Screening, Evaluation, and Treatment of Substance Use Disorder in Chronic Dialysis Patients
All patients on chronic dialysis should undergo universal screening for substance use disorders using validated brief tools, followed by stratified intervention based on severity: brief counseling for hazardous use, intensive follow-up for substance abuse, and combined pharmacotherapy with specialty referral for substance dependence.
Screening Approach
Implement universal screening despite limited direct evidence in dialysis populations, justified by the high prevalence and morbidity of substance use disorders 1. Use one of two validated tools:
Single-Question Screen 1:
- "How many times in the past year have you used an illegal drug or used a prescription medication for nonmedical reasons?"
- Sensitivity: 90-100%, Specificity: 74%
- Any positive response requires further assessment
Drug Abuse Screening Test-10 (DAST-10) 1:
- Self-administered 10-question tool
- Scoring: 0 points = low risk; 1-3 points = moderate risk (monitor and reassess); >3 points = substance abuse or dependence
- Sensitivity: 90-100%, Specificity: 77%
Critical Screening Considerations
Screen for prescription medication misuse explicitly, as this represents the fastest-growing substance use problem with dramatic increases in emergency visits, treatment admissions, and overdose deaths 1. The dialysis population faces particular vulnerability given frequent opioid prescriptions for pain management.
Stratification and Treatment Algorithm
After positive screening, stratify patients into three categories that determine treatment intensity 1:
1. Hazardous Use
Definition: Infrequent use without meeting abuse/dependence criteria, but with potential health consequences
Management:
- Brief motivational interviewing-style counseling by the treating physician 1
- Ongoing assessment at routine visits
- No specialty referral required initially
2. Substance Abuse
Definition: One or more of the following within 12 months 1:
- Failure to fulfill major role obligations
- Recurrent use in physically hazardous situations
- Recurrent substance-related legal problems
- Continued use despite persistent social/interpersonal problems
Management:
- Brief counseling using motivational interviewing approach 1
- Negotiate specific treatment plan
- Close follow-up with frequent reassessment
- If abuse continues despite intervention, refer to specialty treatment 1
3. Substance Dependence
Management requires three components 1:
- Brief counseling using motivational (not confrontational) communication style
- Immediate specialty referral to addiction medicine or behavioral health
- Pharmacotherapy when indicated:
Opioid Use Disorder:
- Buprenorphine (office-based or specialty program) 1
- Methadone (requires specialized program)
- Naltrexone 50 mg daily or 380 mg monthly injection 1
- Monitor liver function tests at baseline and every 3-6 months with naltrexone 1
Alcohol Use Disorder:
- Naltrexone or acamprosate 2
Stimulant Dependence:
Essential Comorbidity Assessment
Screen all patients with substance use disorders for 1:
- Depression and anxiety disorders
- Bipolar disorder
- Post-traumatic stress disorder
- Personality disorders (dependent, antisocial)
- Intimate partner violence
These conditions occur at substantially higher rates in patients with substance use disorders and require concurrent treatment 1.
Referral Resources and Intensity
Match treatment intensity to severity 1:
Outpatient Treatment: For patients with stable living environments
- Group and individual counseling
- Pharmacotherapy management
- Allows continued work and family participation
Residential Treatment: For patients requiring intensive intervention
- Therapeutic community models
- 24-hour structured environment
Mutual Help Meetings: Appropriate at any stage
- Alcoholics Anonymous, Narcotics Anonymous
- Free, widely available, peer-led support
- Can supplement professional treatment
Critical Pitfalls to Avoid
Do not use confrontational communication styles - motivational interviewing approaches improve outcomes 1
Do not delay specialty referral for substance dependence - fewer than 20% of patients needing treatment receive it, and delays worsen outcomes 2
Do not prescribe naltrexone to patients requiring opioids for pain control - it blocks opioid analgesia and precipitates withdrawal 1
Do not overlook prescription medication misuse - explicitly ask about nonmedical use of prescribed medications 1
Do not assume substance use disorders are moral failings - treat as chronic medical conditions like diabetes that require ongoing management 2
Insurance and System-Level Considerations
Health insurance must cover evidence-based substance use disorder treatment with mental health parity 2. This includes medication-assisted treatment, counseling, medical services, mental health services, and family services. Strong oversight ensures adequate coverage of all treatment components 2.
The dialysis care team should facilitate access to prescription drug monitoring programs when available, checking before prescribing controlled substances to identify potential misuse patterns 2.